Literature DB >> 15589317

SOCS-1 and SOCS-3 inhibit IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression in HEK293 cells.

Daniel Hebenstreit1, Petra Luft, Angela Schmiedlechner, Albert Duschl, Jutta Horejs-Hoeck.   

Abstract

Secretion of various chemokines including Eotaxin-3/CCL26 results in the attraction of eosinophils to sites of allergic inflammation. IL-4/IL-13-induced activation of the Eotaxin-3/CCL26 gene in human dermal fibroblasts was shown to be a STAT6-dependent process mediated by a single STAT6 binding motif located upstream of the transcription initiation site. The suppressors of cytokine signaling 1-3 (SOCS 1-3) are members of a recently discovered family of proteins acting as negative regulators of cytokine signaling. We show here, that transfection of SOCS-1 and SOCS-3 but not SOCS-2 expression vectors inhibited IL-4/IL-13 induced secretion of Eotaxin-3/CCL26. Further, using Eotaxin-3/CCL26 promoter reporter gene constructs, we could show that, upon cotransfection of SOCS-1 and SOCS-3 expression vectors, IL-4 and IL-13 induced luciferase activity was strongly reduced. This effect was not seen when SOCS-2 was cotransfected. Further, EMSA studies with nuclear extracts prepared from IL-4/IL-13 induced HEK293 cells were conducted. The nuclear extracts of cells transfected with SOCS-1 or SOCS-3 did not form complexes with oligonucleotide probes corresponding to the STAT6 binding site in the Eotaxin-3/CCL26 promoter. In contrast, complex formation upon SOCS-2-transfection was comparable to mock-transfected cells. Further, the levels of phosphorylated STAT6 in IL-4 and IL-13 treated cells were markedly reduced when the cells had been transfected with SOCS-1 or SOCS-3, confirming the role of these negative regulators for the IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression. The insertion of amino acid exchanges into the kinase inhibitory regions of SOCS-1 and SOCS-3 demonstrated a requirement of these domains for a proper inhibitory function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15589317     DOI: 10.1016/j.molimm.2004.09.004

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  23 in total

1.  IL-4 independent nuclear translocalization of STAT6 in HeLa cells by entry of Toxoplasma gondii.

Authors:  Hye-Jin Ahn; Ji Yeon Kim; Ho-Woo Nam
Journal:  Korean J Parasitol       Date:  2009-05-27       Impact factor: 1.341

2.  17β-Estradiol protects the esophageal epithelium from IL-13-induced barrier dysfunction and remodeling.

Authors:  Justin C Wheeler; Simone Vanoni; Chang Zeng; Lisa Waggoner; Yanfen Yang; David Wu; Jazib Uddin; Rebekah Karns; Leah Kottyan; Vincent Mukkada; Marc E Rothenberg; Simon P Hogan
Journal:  J Allergy Clin Immunol       Date:  2018-12-20       Impact factor: 10.793

3.  Respiratory syncytial virus infection induces a subset of types I and III interferons in human dendritic cells.

Authors:  Philippa Hillyer; Viraj P Mane; Aaron Chen; Maria B Dos Santos; Lynnsie M Schramm; Rachel E Shepard; Cindy Luongo; Cyril Le Nouën; Lei Huang; Lihan Yan; Ursula J Buchholz; Ronald G Jubin; Peter L Collins; Ronald L Rabin
Journal:  Virology       Date:  2017-01-31       Impact factor: 3.616

4.  IL-17A enhances IL-13 activity by enhancing IL-13-induced signal transducer and activator of transcription 6 activation.

Authors:  Sara L Hall; Theresa Baker; Stephane Lajoie; Phoebe K Richgels; Yanfen Yang; Jaclyn W McAlees; Adelaide van Lier; Marsha Wills-Karp; Umasundari Sivaprasad; Thomas H Acciani; Timothy D LeCras; Jocelyn Biagini Myers; Melinda Butsch Kovacic; Ian P Lewkowich
Journal:  J Allergy Clin Immunol       Date:  2016-06-11       Impact factor: 10.793

Review 5.  SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?

Authors:  R Mahony; S Ahmed; C Diskin; N J Stevenson
Journal:  Cell Mol Life Sci       Date:  2016-05-02       Impact factor: 9.261

Review 6.  Proton pump inhibitor responsive esophageal eosinophilia, a distinct disease entity?

Authors:  William Munday; Xuchen Zhang
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

7.  STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction.

Authors:  Michael J Rosen; Mark R Frey; M Kay Washington; Rupesh Chaturvedi; Lindsay A Kuhnhein; Poojitha Matta; Frank L Revetta; Keith T Wilson; D Brent Polk
Journal:  Inflamm Bowel Dis       Date:  2011-02-09       Impact factor: 5.325

8.  Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.

Authors:  Hui-Ming Chen; William van der Touw; Yuan Shuo Wang; Kyeongah Kang; Sunny Mai; Jilu Zhang; Dayanira Alsina-Beauchamp; James A Duty; Sathish Kumar Mungamuri; Bin Zhang; Thomas Moran; Richard Flavell; Stuart Aaronson; Hong-Ming Hu; Hisashi Arase; Suresh Ramanathan; Raja Flores; Ping-Ying Pan; Shu-Hsia Chen
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

9.  Regulation of eotaxin-3/CC chemokine ligand 26 expression by T helper type 2 cytokines in human colonic myofibroblasts.

Authors:  K Takahashi; H Imaeda; T Fujimoto; H Ban; S Bamba; T Tsujikawa; M Sasaki; Y Fujiyama; A Andoh
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

10.  Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD.

Authors:  Edaire Cheng; Xi Zhang; Xiaofang Huo; Chunhua Yu; Qiuyang Zhang; David H Wang; Stuart Jon Spechler; Rhonda F Souza
Journal:  Gut       Date:  2012-05-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.